To measure or to estimate? A comparison between indirect calorimetry and predictive equations for resting metabolic rate in institutionalized older adults: a systematic review.

Arch Gerontol GeriatrSep 10, 2026 (epub)
Clinical ResearchGeriatrics

Thonny Richardy Piassa, Aida Maria Borges Da Silva, Ligiana Pires Corona

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the accuracy of resting metabolic rate (RMR) predictive equations compared to indirect calorimetry in institutionalized older adults. Analyzing four studies with 332 participants, it was found that 79% of predictive equations overestimated RMR, with individual accuracy not exceeding 41%. The Lührmann equation showed moderate quality of evidence.

Key findings

  • 79% of predictive equations overestimated RMR at the group level.
  • Individual accuracy of RMR estimates did not exceed 41%.
  • The Lührmann equation demonstrated acceptable performance.
  • Classic formulas like Harris-Benedict showed low accuracy.

Why it matters

Accurate estimation of resting metabolic rate is crucial for nutritional management in older adults, particularly in long-term care settings, to prevent adverse health outcomes. Misestimation can lead to inappropriate dietary prescriptions.

Source

PubMed · PMID 42759166

Published in Arch Gerontol Geriatr. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.